DXNVX, Smooth Progress in Expanding Global New Drug Pipeline Development

KOSDAQ-listed company Dx&Vx announced on the 16th that with the addition of world-renowned infectious disease expert Professor Namjun Cho, it will participate in the 'Disease X' response project led by him, currently being conducted at Stanford University and the U.S. National Institutes of Health (NIH).

'Disease X' is a project led by Professor Namjun Cho, supported by the U.S. National Institutes of Health (NIH) and Stanford University, receiving a total funding of $2.23 million to be carried out until 2027.

Professor Cho, who is a Chair Professor at Nanyang Technological University in Singapore and also serves as the project leader of the Antiviral Drug Discovery Centers for Pathogens of Pandemic Center at Stanford School of Medicine, stated, "I sympathize with CEO Jongyun Lim’s goal of 'commercializing everything related to microbes,' and decided to join Dx&Vx to realize this vision together."

The new drugs being developed at Stanford University and affiliated companies consist of innovative technologies and substances necessary to prevent and treat previously unknown viral pandemics, with plans to license technology for at least three or more substances.

These technologies will first be licensed to Dx&Vx, and subsequently, through collaboration with Hanmi Pharmaceutical Group and Kori Group, the company plans to accelerate project commercialization and the development of a global new drug pipeline.

A Dx&Vx representative stated, "To commercialize the project, we plan to accelerate the introduction of innovative infectious disease vaccine manufacturing technologies through close cooperation with Hanmi Pharmaceutical Group and Kori Group, and speed up the expansion of infectious disease vaccine development infrastructure to prepare for the future 'Disease X'."

In particular, the representative added, "Regarding obesity treatments, which have recently attracted significant global market interest, we are currently preparing early patent applications for multiple substances and will concurrently conduct additional studies such as animal testing."